Biotech News
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
ir.corcept.com2026-05-06 15:28 EST
2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 REDWOOD CITY, Calif. --(BUSINESS WIRE)--Feb. 24, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a